Top

Sleep and Breathing

Published in:

01-06-2012 | Original Article

Oxidative and carbonyl stress in patients with obstructive sleep apnea treated with continuous positive airway pressure

Authors: Peter Celec, Július Hodosy, Michal Behuliak, Roland Pálffy, Roman Gardlík, Lukáč Halčák, Imrich Mucska

Published in: Sleep and Breathing | Issue 2/2012

Abstract

Purpose

The pathogenesis of cardiovascular complications of obstructive sleep apnea syndrome (OSAS) can be explained by oxidative and carbonyl stress due to oxygenation and reoxygenation injury during sleep. This hypothesis has yet to be proved experimentally, although several clinical observations have found increased oxidative damage in plasma. Continuous positive airway pressure (CPAP) improves symptoms and prognosis of patients with OSAS.

Methods

Patients with confirmed SAS (n = 89) underwent polysomnography and received CPAP treatment. Plasma and saliva samples were taken before CPAP therapy as well as after 1 and 6 months of CPAP treatment. Selected markers of oxidative and carbonyl stress were measured in plasma and saliva, and their dynamics was statistically analyzed.

Results

Plasma levels of thiobarbituric acid reacting substances—a marker of lipoperoxidation—and advanced glycation end products (AGEs)—a marker of carbonyl stress—were decreased by the CPAP therapy. The decrease of AGEs and fructosamine was also found in saliva. Interestingly, no gender differences and no changes of antioxidant status measured as total antioxidant capacity and ferrous reducing ability were found in either of the samples.

Conclusion

Previous findings of lowered plasma markers of oxidative stress were confirmed. Plasma AGEs were lowered by CPAP therapy. This is the first study analyzing markers of oxidative and carbonyl stress in saliva. Non-invasive sampling of saliva makes it a very interesting source of information for repeated monitoring of therapy success. Salivary AGEs and fructosamine as markers of carbonyl stress were decreased by the CPAP therapy and might therefore have potential informative value for clinical observations, as well as for the understanding of the pathogenesis of OSAS complications.

Jurkovicova I, Celec P (2004) Sleep apnea syndrome and its complications. Acta Med Austriaca 31:45–50PubMed

Lavie L, Lavie P (2009) Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J 33:1467–1484PubMedCrossRef

Miyata T, de Strihou CV, Kurokawa K, Baynes JW (1999) Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int 55:389–399PubMedCrossRef

Streckfus CF, Bigler LR (2002) Saliva as a diagnostic fluid. Oral Dis 8:69–76PubMedCrossRef

Celec P, Hodosy J, Celecova V, Vodrazka J, Cervenka T, Halcak L, Bozek P, Kopani M, Kudela M (2005) Salivary thiobarbituric acid reacting substances and malondialdehyde—their relationship to reported smoking and to parodontal status described by the papillary bleeding index. Dis Markers 21:133–137PubMed

Becker HF, Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan CE, Peter JH (2003) Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107:68–73PubMedCrossRef

Kaneko Y, Floras JS, Usui K, Plante J, Tkacova R, Kubo T, Ando S, Bradley TD (2003) Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 348:1233–1241PubMedCrossRef

Marin JM, Carrizo SJ, Vicente E, Agusti AGN (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea–hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365:1046–1053PubMed

Murri M, Alcazar-Ramirez J, Garrido-Sanchez L, Linde F, Alcaide J, Cardona F, Tinahones FJ (2009) Oxidative stress and metabolic changes after continuous positive airway pressure treatment according to previous metabolic disorders in sleep apnea–hypopnea syndrome patients. Transl Res 154:111–121PubMedCrossRef

10.

Christou K, Kostikas K, Pastaka C, Tanou K, Antoniadou I, Gourgoulianis KI (2009) Nasal continuous positive airway pressure treatment reduces systemic oxidative stress in patients with severe obstructive sleep apnea syndrome. Sleep Med 10:87–94PubMedCrossRef

11.

Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ (2003) 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 124:1386–1392PubMedCrossRef

12.

Moser D, Anderer P, Gruber G, Parapatics S, Loretz E, Boeck M, Kloesch G, Heller E, Schmidt A, Danker-Hopfe H, Saletu B, Zeitlhofer J, Dorffner G (2009) Sleep classification according to AASM and Rechtschaffen & Kales: effects on sleep scoring parameters. Sleep 32:139–149PubMed

13.

Hodosy J, Celec P (2005) Daytime of sampling, tooth-brushing and ascorbic acid influence salivary thiobarbituric acid reacting substances—a potential clinical marker of gingival status. Dis Markers 21:203–207PubMed

14.

Ohkawa H, Ohishi N, Yagi K (1978) Reaction of linoleic acid hydroperoxide with thiobarbituric acid. J Lipid Res 19:1053–1057PubMed

15.

Witko-Sarsat V, Friedlander M, CapeillereBlandin C, NguyenKhoa T, Nguyen NT, Zingraff J, Jungers P, DescampsLatscha B (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304–1313PubMedCrossRef

16.

Munch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, Niwa T, Lemke HD, Schinzel R (1997) Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 35:669–677PubMed

17.

San-Gil F, Schier GM, Moses RG, Gan IE (1985) Improved estimation of fructosamine, as a measure of glycated serum protein, with the Technicon RA-1000 analyzer. Clin Chem 31:2005–2006PubMed

18.

Erel O (2004) A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37:277–285PubMedCrossRef

19.

Benzie IFF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 239:70–76PubMedCrossRef

20.

Dikmenoglu N, Ciftci B, Ileri E, Guven SF, Seringec N, Aksoy Y, Ercil D (2006) Erythrocyte deformability, plasma viscosity and oxidative status in patients with severe obstructive sleep apnea syndrome. Sleep Med 7:255–261PubMedCrossRef

21.

Jordan W, Cohrs S, Degner D, Meier A, Rodenbeck A, Mayer G, Pilz J, Ruther E, Kornhuber J, Bleich S (2006) Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome. J Neural Transm 113:239–254PubMedCrossRef

22.

Selmi C, Montano N, Furlan R, Keen CL, Gershwin ME (2007) Inflammation and oxidative stress in obstructive sleep apnea syndrome. Exp Biol Med 232:1409–1413CrossRef

23.

Ozkan Y, Firat H, Simsek B, Torun M, Yardim-Akaydin S (2008) Circulating nitric oxide (NO), asymmetric dimethylarginine (ADMA), homocysteine, and oxidative status in obstructive sleep apnea–hypopnea syndrome (OSAHS). Sleep Breath 12:149–154PubMedCrossRef

24.

Ryan S, Taylor CT, McNicholas WT (2005) Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112:2660–2667PubMedCrossRef

25.

Greenberg H, Ye XB, Wilson D, Htoo AK, Hendersen T, Liu SF (2006) Chronic intermittent hypoxia activates nuclear factor-kappa B in cardiovascular tissues in vivo. Biochem Biophys Res Commun 343:591–596PubMedCrossRef

26.

Suzuki YJ, Jain V, Park AM, Day RM (2006) Oxidative stress and oxidant signaling in obstructive sleep apnea and associated cardiovascular diseases. Free Radic Biol Med 40:1683–1692PubMedCrossRef

27.

Yamauchi M, Kimura H (2008) Oxidative stress in obstructive sleep apnea: putative pathways to the cardiovascular complications. Antioxid Redox Signal 10:755–768PubMedCrossRef

28.

Lykkesfeldt J (2007) Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta 380:50–58PubMedCrossRef

29.

WitkoSarsat V, Friedlander M, CapeillereBlandin C, NguyenKhoa T, Nguyen NT, Zingraff J, Jungers P, DescampsLatscha B (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304–1313CrossRef

30.

Capeillere-Blandin C, Gausson V, Descamps-Latscha B, Witko-Sarsat V (2004) Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta Mol Basis Dis 1689:91–102

31.

Hernandez C, Abreu J, Abreu P, Colino R, Jimenez A (2006) Effects of nasal positive airway pressure treatment on oxidative stress in patients with sleep apnea–hypopnea syndrome. Arch Bronconeumol 42:125–129PubMedCrossRef

32.

Takahashi KI, Chin K, Nakamura H, Morita S, Sumi K, Oga T, Matsumoto H, Niimi A, Fukuhara S, Yodoi J, Mishima M (2008) Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. Antioxid Redox Signal 10:715–726PubMedCrossRef

33.

Lavie P, Lavie L (2009) Unexpected survival advantage in elderly people with moderate sleep apnoea. J Sleep Res 18:397–403PubMedCrossRef

34.

Grebe M, Eisele HJ, Weissmann N, Schaefer C, Tillmanns H, Seeger W, Schulz R (2006) Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J Respir Crit Care Med 173:897–901PubMedCrossRef

Title: Oxidative and carbonyl stress in patients with obstructive sleep apnea treated with continuous positive airway pressure
Authors: Peter Celec
Július Hodosy
Michal Behuliak
Roland Pálffy
Roman Gardlík
Lukáč Halčák
Imrich Mucska
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Sleep and Breathing / Issue 2/2012
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-011-0510-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2012

Clinical presentation of shift workers to a sleep clinic

Is automatic CPAP titration as effective as manual CPAP titration in OSAHS patients? A meta-analysis

Head-and-neck paragangliomas are associated with sleep-related complaints, especially in the presence of carotid body tumors

Increased systemic inflammation overnight correlates with insulin resistance among children evaluated for obstructive sleep apnea

Association between osteoporosis and sleep duration in healthy middle-aged and elderly adults: a large-scale, cross-sectional study in Japan

Effects of chronic intermittent hypoxia on genioglossus in rats

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials